Harvard Bioscience Q3 net loss more than doubles to $2.6 million; revenue rises 8% to $22.2 million
HBIO•Harvard Bioscience’s third-quarter 2026 net loss more than doubled year over year to $2.6 million, while revenue rose 8% to $22.2 million. The company reaffirmed full-year 2026 revenue growth guidance of 3%-5%.
1. Quarterly results and outlook
Harvard Bioscience reported a third-quarter 2026 net loss of $2.6 million, more than double the year-earlier loss, as revenue increased 8% to $22.2 million. The company reaffirmed its full-year 2026 revenue growth guidance of 3%-5% and said Project Viking remains on track for completion by the end of the first quarter of 2027.
